Cardiac protection effect of Xuezhikang on patients with chronic heart failure correlates positively to lowering plasma brain natriuretic peptide levels

Abstract

Abstract: AIM: To observe the cardiac protection effect of Xuezhikang on cardiac function in patients with chronic heart failure (CHF) and its relation with plasma N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity high-sensitivity C-reactive protein (HS-CRP) levels. METHODS: 80 patients with CHF were randomly divided into two groups;the control group received routine anti-failure treatment, and the observation group received routine anti-failure treatment in combination with Xuezhikang for 8 weeks. The cardiac function, i.e., left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVDd) , were measured before and after treatment with color Doppler ultrasound; plasma NT-proBNP, HS-CRP levels were determined by ELISA method and nephelometry respectively. RESULTS: The cardiac function improved more effectively in the observation group than that in the control group. The LVEF increasing and LVDd decreasing were correlated to plasma NT-proBNP levels (r=-0.72 and 0.75, P<0.05 respectively ) and HS-CRP levels (r=-0.387 and 0.31, P<0.05). CONCLUSION: Xuezhikang is effective in anti-failure treatment. Reducing plasma NT-proBNP and HS-CRP levels may be the possible mechanism of the drug, but NT-proBNP reducing is more important.

Key words: Chronic heart failure, N-terminal pro-brain natriuretic peptide, High-sensitivity C-reactive protein, Xuezhikang

CLC Number:

R541
R969.4

LIAO Xiang-ming. Cardiac protection effect of Xuezhikang on patients with chronic heart failure correlates positively to lowering plasma brain natriuretic peptide levels[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2010, 15(11): 1284-1287.

References

[1] Patton KK, Ellinor PT, Heckbert SR, et al. N-terminal pro-B-type natriuretic peptide is a major predictor for the development of atrial fibrillation[J]. Circulation, 2009,120:1768-1774.
[2] 赖长春,高伟栋, 李浙成, 等. 慢性心力衰竭时脑钠肽和C反应蛋白水平及卡维地洛的疗效[J]. 岭南心血管病杂志, 2007, 13(5):340 - 343.
[3] Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastain on the incidence of heart failure in patients with coronary heart disease [J]. J Card Fail , 1997, 3(4) :249 - 254.
[4] Lewis SJ, Moye LA, Sacks FM, et al. Effect of privation on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range[J]. Ann Intern Med, 1998,129(9) :681 - 689.
[5] 王银叶, 韦薇, 李长龄.特种红曲对鹌鹑实验性脂肪肝的治疗作用[J].中国临床药理学与治疗学,2002, 7(4):293-295.
[6] 刘丽娟,马世尧,刘斯春.血脂康的药理作用及临床评价[J].中国药房,2003,14(3):184-186.
[7] 王涛. 氟伐他汀、血脂康治疗冠心病伴高血脂患者的疗效观察[J].中国医药导报,2009,6(4):46-47.
[8] 刘尊齐 ,崔连群 ,王勇 ,等.大剂量血脂康在经皮冠状动脉介入术中的炎症抑制作用 [J].中国病理生理杂志, 2007, 23(9) :1703 - 1705.
[9] Odar-Cederlöf I, Bjellemp P, Williams A, et al. Daily dialyses decrease plasma levels of brain natriuretic peptide (BNP) , a biomarker of left ventricular dysfunction [J]. Hemodial Int , 2006 ,10(4) :394 - 398,
[10] Tmugflton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma amino terminal brain natriuretic peptide (N-BNP) concentrations [J]. Lancet , 2000 , 355(9210) :1126 - 1130.
[11] Node K, Fujita M, Kitakaze M, et al. Short term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy [J]. Circulation , 2003 ,108(7) :839 - 843.
[12] 刘鹏,卢长青,宋文翔,等.血脂康对冠心病患者介入治疗后高敏C反应蛋白的影响[J]. 郑州大学学报:医学版, 2009,44(1):154-156.
[13] 唐永亮, 张子诚, 苏东升,等.血脂康对脑梗死患者颈动脉粥样硬化斑块及C 反应蛋白的影响[J]. 中国实用神经疾病杂志,2010,13(13):13-15.